Aston Sci
Updated: February 04, 2026
Hun Jung, CEO
Country: South Korea | Funding: ₩27B (+)
Founded: 2018
Website: http://astonsci.com
Aston Sci develops cancer vaccines based on mRNA, DNA and peptides, which are currently being evaluated for efficacy in breast and gastric cancer. The company has created a cloud-based Collaborative Drug Discovery platform, powered by the Th-Vac AI epitope screening system and supported by an antigen-based epitope prediction program. Using the platform's results, the company performs precise immunological screening, enabling the identification of highly selective epitopes specific to MHC class II, known for their ability to induce strong and sustained CD4⁺ T-cell immunity. By integrating multi-omics datasets with machine learning, Th-Vac overcomes key barriers in the development of off-the-shelf vaccines encoding TAAs (tumor-associated antigens) or TCAs (tumor-specific antigens), as well as personalized neoantigen vaccines, including tumor heterogeneity, lengthy manufacturing lead times, and limited patient applicability.
Founded: 2018
Website: http://astonsci.com
Aston Sci develops cancer vaccines based on mRNA, DNA and peptides, which are currently being evaluated for efficacy in breast and gastric cancer. The company has created a cloud-based Collaborative Drug Discovery platform, powered by the Th-Vac AI epitope screening system and supported by an antigen-based epitope prediction program. Using the platform's results, the company performs precise immunological screening, enabling the identification of highly selective epitopes specific to MHC class II, known for their ability to induce strong and sustained CD4⁺ T-cell immunity. By integrating multi-omics datasets with machine learning, Th-Vac overcomes key barriers in the development of off-the-shelf vaccines encoding TAAs (tumor-associated antigens) or TCAs (tumor-specific antigens), as well as personalized neoantigen vaccines, including tumor heterogeneity, lengthy manufacturing lead times, and limited patient applicability.
